In this episode of SARC Talk Journal Club, our panel discusses the Brightline-1 Phase II/III trial, evaluating brigimadlin (BI 907828) versus doxorubicin as first-line treatment for patients with advanced, MDM2-amplified dedifferentiated liposarcoma (DDLPS).

The panel reviews the study design, progression-free survival, objective response rates, safety findings, and translational data surrounding this novel MDM2-p53 antagonist. We explore what the results tell us about targeting the MDM2-p53 pathway and the ongoing challenges of developing new treatments for advanced DDLPS.

Join us for an expert discussion of this important sarcoma clinical trial and what the findings may mean for future liposarcoma research, targeted therapies, and clinical trial development.

Abstract: https://pubmed.ncbi.nlm.nih.gov/42268294/

In this episode of SARC Talk Journal Club, our panel discusses the EURO EWING 2012 Phase III trial, evaluating whether adding zoledronic acid to consolidation chemotherapy could improve outcomes for patients with Ewing sarcoma and Ewing-like sarcomas.

The panel reviews the study design, key findings, event-free and overall survival outcomes, and the implications of adding zoledronic acid to treatment. What can this trial teach us about translating promising preclinical findings into clinical practice?

Join us for an expert discussion of this important Ewing sarcoma clinical trial and what the results mean for future sarcoma research and treatment.

In this episode of SARC Talk Journal Club, our panel discusses the MANEUVER Phase III trial published in The Lancet, evaluating pimicotinib versus placebo in patients with tenosynovial giant cell tumor (TGCT). We review the study design, efficacy, safety profile, and patient-reported outcomes while exploring what these findings could mean for the treatment of unresectable, symptomatic TGCT.

Join us as we examine the evidence behind this promising CSF-1R inhibitor and discuss its potential impact on clinical practice and future research in sarcoma.

In this episode of SARC Talk Journal Club, we review the recent Lancet Oncology phase II trial evaluating the combination of cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas. Our panel examines the study design, efficacy, safety profile, and clinical implications, discussing whether this combination represents a promising new treatment option and what questions remain for future research.